3-氟-4-(2-(吡咯烷-1-基)乙氧基)苯胺 | 837421-94-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 3-氟-4-(2-(吡咯烷-1-基)乙氧基)苯胺
• 英文名称: [3-fluoro-4-(2-pyrrolidin-1-ylethoxy)phenyl]amine
• 英文别名: 3-fluoro-4-(2-(pyrrolidin-1-yl)ethoxy)aniline；(3-fluoro-4-{[2-(1-pyrrolidinyl)ethyl]oxy}phenyl)amine；3-fluoro-4-(2-pyrrolidin-1-ylethoxy)aniline
• CAS: 837421-94-0
• 化学式: C₁₂H₁₇FN₂O
• mdl: MFCD08699628
• 分子量: 224.278
• InChiKey: ZXDAQTQQLCSQEM-UHFFFAOYSA-N

物化性质

• 沸点：
  371.2±32.0 °C(Predicted)
• 密度：
  1.166±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.5
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  3-氟-4-(2-(吡咯烷-1-基)乙氧基)苯胺 、 6-chloro-N-(2,6-dichlorophenyl)-1-(3-methoxy-3-methylbutyl)-1H-pyrazolo[3,4-d]pyrimidin-3-amine 在 三氟乙酸 作用下， 以 1,4-二氧六环 、 正丁醇 为溶剂， 生成 N3-(2,6-dichlorophenyl)-N6-(3-fluoro-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1-(3-methoxy-3-methyl-butyl)-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
  参考文献：
  名称：

  Identification and optimization of N3,N6-diaryl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors

  摘要：

  A new series of pyrazolo[3,4-d]pyrimidine-3,6-diamines was designed and synthesized as potent and selective inhibitors of the nonreceptor tyrosine kinase, ACK1. These compounds arose from efforts to rigidify an earlier series of N-aryl pyrimidine-5-carboxamides. The synthesis and structure-activity relationships of this new series of inhibitors are reported. The most promising compounds were also profiled for their pharmacokinetic properties.

  DOI：

  10.1016/j.bmcl.2008.10.092
• 作为产物：
  描述：

  2-氟-4-硝基苯酚 在 palladium on activated charcoal 、 氢气 、 caesium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.5h， 生成 3-氟-4-(2-(吡咯烷-1-基)乙氧基)苯胺
  参考文献：
  名称：

  Discovery of biphenyl-based VEGFR-2 inhibitors. Part 3: Design, synthesis and 3D-QSAR studies

  摘要：

  VEGFR-2 plays an essential role in angiogenesis and is a central target for anticancer drug discovery. In order to develop novel VEGFR-2 inhibitors, we designed and synthesized 33 biphenyl amides based on our previously reported lead compound. The biological results indicated that four compounds (18b, 20e, 20h and 20j) are potent VEGFR-2 inhibitors which are comparable to positive control. Compound 18b displayed the most potent VEGFR-2 inhibition with IC50 value of 2.02 nM. Moreover, it exhibited promising antiproliferative activity against MCF-7 and SMMC-7721 cells with IC50 values of 1.47 mu M and 5.98 mu M, respectively. Molecular docking and 3D-QSAR studies were also carried out. The results indicated that these biphenyl amides could serve as promising leads for further optimization as novel VEGFR-2 inhibitors. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.01.006

文献信息

• [EN] THIAZOLE AND OXAZOLE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE À BASE DE THIAZOLE ET D'OXAZOLE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009076140A1

  公开（公告）日：2009-06-18

  The present invention provides thiazole and oxazole compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

  本发明提供了噻唑和恶唑化合物、含有该化合物的组合物，以及它们的制备方法和作为药物的应用方法。
• [EN] CYCLIN-DEPENDENT KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES CYCLINE-DÉPENDANTES
  申请人：SPV THERAPEUTICS INC

  公开号：WO2020140055A1

  公开（公告）日：2020-07-02

  Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are useful in the treatment or alleviation of protein kinase associated disorders, including cancer, infectious diseases, autoimmune diseases, or cardiovascular diseases.

  本文描述了化合物及其药用盐，以及它们的药物组合物，治疗方法和医疗用途。本文描述的化合物是细胞周期依赖性激酶的调节剂，并且在治疗或缓解蛋白激酶相关疾病方面具有用途，包括癌症，传染病，自身免疫疾病或心血管疾病。
• Heterocyclic compounds as ligands of the GABAA receptor
  申请人：——

  公开号：US20030105081A1

  公开（公告）日：2003-06-05

  Disclosed are heterocyclic compounds of the formula 1 and the pharmaceutically acceptable salts thereof wherein the variables A, V, Y, J, E, X, T, G, Q, W, Z, b, n and m are defined herein. These compounds are highly selective agonists, antagonists or inverse agonists for GABA A brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABA A brain receptor.

  揭示了具有以下公式的杂环化合物及其药用可接受的盐，其中变量A、V、Y、J、E、X、T、G、Q、W、Z、b、n和m在此处被定义。这些化合物是GABA A 脑受体的高度选择性激动剂、拮抗剂或逆激动剂，或者是GABA A 脑受体的激动剂、拮抗剂或逆激动剂的前药。
• 具有抗肿瘤活性的联苯酰胺化合物及其制备方 法和应用
  申请人：西安交通大学

  公开号：CN104016879B

  公开（公告）日：2016-02-24

  本发明公开了一种具有抗肿瘤活性的联苯酰胺化合物及其制备方法和应用，该化合物的结构式为，其中R1为氢或卤素，R2为末端由叔胺基取代的碳原子数为1～4的烷氧基，通过氧原子连接于酰胺的对位。该化合物体外对肿瘤细胞有很好的抑制活性，可用于抗肿瘤药物的制备，尤其是抗肝癌药物和抗乳腺癌药物。本发明提供的联苯酰胺化合物的制备方法，具有原料易得，反应条件温和，反应过程操作简单，所用试剂便宜的优点。
• Pyrrolopyrimidinyl axl kinase inhibitors
  申请人：Vankayalapati Hariprasad

  公开号：US20100204221A1

  公开（公告）日：2010-08-12

  Compounds represented by Formula (I): are useful in treating diseases, such as cancer, that are mediated and/or associated (at least in part) with Axl kinase. The compounds can be formulated as pharmaceutically acceptable compositions for administration to a subject in need thereof.

  由公式（I）表示的化合物在治疗通过Axl激酶介导和/或相关（至少部分相关）的疾病，如癌症方面具有用处。这些化合物可以制备成药学上可接受的组合物，用于给需要的受试者。